KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Non-Current Debt readings, the most recent being $194.4 million for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 38.17% to $194.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $194.4 million, a 38.17% decrease, with the full-year FY2024 number at $314.9 million, up 3.84% from a year prior.
  • Non-Current Debt hit $194.4 million in Q3 2025 for Biocryst Pharmaceuticals, down from $242.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $315.4 million in Q1 2025 to a low of $123.0 million in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $232.5 million (2023), compared with a mean of $231.0 million.
  • Biggest five-year swings in Non-Current Debt: soared 391.02% in 2021 and later crashed 38.17% in 2025.
  • Biocryst Pharmaceuticals' Non-Current Debt stood at $136.1 million in 2021, then soared by 70.21% to $231.6 million in 2022, then surged by 30.92% to $303.2 million in 2023, then rose by 3.84% to $314.9 million in 2024, then tumbled by 38.27% to $194.4 million in 2025.
  • The last three reported values for Non-Current Debt were $194.4 million (Q3 2025), $242.8 million (Q2 2025), and $315.4 million (Q1 2025) per Business Quant data.